Trial Profile

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 03 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 007F (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Pharmacodynamics

Most Recent Events

21 Apr 2022 Status changed from recruiting to completed.
09 Dec 2019 According to a Gracell Biotechnology media release, till Nov 2019, 37 patients are enrolled in this study from eight clinical centers.
09 Dec 2019 According to a Gracell Biotechnology media release, data (n=35) from this study were presented at the American Society of Hematology (ASH) Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com